{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:51:33Z","timestamp":1777395093120,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Anesth\/J Can Anesth"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12630-015-0480-2","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T17:40:23Z","timestamp":1441993223000},"page":"1303-1307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Failure of metyrosine therapy for preoperative management of pheochromocytoma: a case report","\u00c9chec du traitement par m\u00e9tyrosine pour la gestion pr\u00e9op\u00e9ratoire d\u2019un ph\u00e9ochromocytome: une \u00e9tude de cas"],"prefix":"10.1007","volume":"62","author":[{"given":"Kabilan","family":"Thanapaalasingham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 S.","family":"Pollmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Schelew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,11]]},"reference":[{"key":"480_CR1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99: 1915-42.","journal-title":"J Clin Endocrinol Metab"},{"key":"480_CR2","first-page":"802","volume":"58","author":"CM Beard","year":"1983","unstructured":"Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983; 58: 802-4.","journal-title":"Mayo Clin Proc"},{"key":"480_CR3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/jcan.2002.124150","volume":"16","author":"MA Kinney","year":"2002","unstructured":"Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002; 16: 359-69.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"480_CR4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0889-8537(21)00620-9","volume":"5","author":"MF Roizen","year":"1987","unstructured":"Roizen MF, Schreider BD, Hassan SZ. Anesthesia for patients with pheochromocytoma. Anesthesiol Clin North America 1987; 5: 269-75.","journal-title":"Anesthesiol Clin North America"},{"key":"480_CR5","author":"M Livingstone","year":"2015","unstructured":"Livingstone M, Duttchen K, Thompson J, et al. Hemodynamic stability during pheochromocytoma resection: lessons learned over the last two decades. Ann Surg Oncol 2015. DOI: 10.1245\/s10434-015-4519-y .","journal-title":"Ann Surg Oncol"},{"key":"480_CR6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12630-014-0232-8","volume":"62","author":"R Merchant","year":"2015","unstructured":"Merchant R, Chartrand D, Dain S, et al. Guidelines to the practice of anesthesia \u2013 revised edition 2015. Can J Anesth 2015; 62: 54-79.","journal-title":"Can J Anesth"},{"key":"480_CR7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-198121020-00001","volume":"21","author":"RN Brogden","year":"1981","unstructured":"Brogden RN, Heel RC, Speight TM, Avery GS. \u03b1-Methyl-p-Tyrosine: a review of its pharmacology and clinical use. Drugs 1981; 21: 81-9.","journal-title":"Drugs"},{"key":"480_CR8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1172\/JCI105754","volume":"47","author":"K Engelman","year":"1968","unstructured":"Engelman K, Horwitz D, Jequier E, Sjoerdsma A. Biochemical and pharmacologic effects of alpha-meythltyrosine in man. J Clin Invest 1968; 47: 577-94.","journal-title":"J Clin Invest"},{"key":"480_CR9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2042018812437356","volume":"3","author":"R Darr","year":"2012","unstructured":"Darr R, Lenders JW, Hofbauer LC, Naumann B, Bornstein SR, Eisenhofer G. Pheochromocytoma\u2014update on disease management. Ther Adv Endocrinol Metab 2012; 3: 11-26.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"480_CR10","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","volume":"92","author":"K Pacak","year":"2007","unstructured":"Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069-79.","journal-title":"J Clin Endocrinol Metab"},{"key":"480_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jch.12084","volume":"15","author":"L Fishbein","year":"2013","unstructured":"Fishbein L, Orlowski R, Cohen D. Pheochromocytoma\/paraganglioma: review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma. J Clin Hypertens (Greenwich) 2013; 15: 428-34.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"480_CR12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archinte.1997.00440290087009","volume":"157","author":"J Steinsapir","year":"1997","unstructured":"Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosine and pheochromocytoma. Arch Intern Med 1997; 157: 901-6.","journal-title":"Arch Intern Med"},{"key":"480_CR13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00000658-199011000-00010","volume":"212","author":"RR Perry","year":"1990","unstructured":"Perry RR, Keiser HR, Norton JA, et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg 1990; 212: 621-8.","journal-title":"Ann Surg"},{"key":"480_CR14","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1001\/archinte.1983.00350120115025","volume":"143","author":"JB Hauptman","year":"1983","unstructured":"Hauptman JB, Modlinger RS, Ertel NH. Pheochromocytoma resistant to alpha-adrenergic blockade. Arch Intern Med 1983; 143: 2321-3.","journal-title":"Arch Intern Med"},{"key":"480_CR15","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/archinte.1985.00360110190038","volume":"145","author":"CV Ram","year":"1985","unstructured":"Ram CV, Meese R, Hill SC. Failure of alpha-methyltryosine to prevent hypertensive crisis in pheochromocytoma. Arch Intern Med 1985; 145: 2114-5.","journal-title":"Arch Intern Med"},{"key":"480_CR16","first-page":"449","volume":"115","author":"O Kuchel","year":"1990","unstructured":"Kuchel O, Buu NT, Edwards DJ. Alternative catecholamine pathways after tyrosine hydroxylase inhibition in malignant pheochromocytoma. J Lab Clin Med 1990; 115: 449-53.","journal-title":"J Lab Clin Med"},{"key":"480_CR17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2125.1976.tb00637.x","volume":"3","author":"DA Richards","year":"1976","unstructured":"Richards DA, Tuckman J, Prichard BN. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol 1976; 3: 849-55.","journal-title":"Br J Clin Pharmacol"},{"key":"480_CR18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/j.1875-9114.1983.tb03252.x","volume":"3","author":"EP MacCarthy","year":"1983","unstructured":"MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy 1983; 3: 193-219.","journal-title":"Pharmacotherapy"},{"key":"480_CR19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/ALN.0b013e318210483d","volume":"114","author":"S Herroeder","year":"2011","unstructured":"Herroeder S, Schonherr ME, DeHert SG, Hollmann MW. Magnesium\u2014essentials for anesthesiologists. Anesthesiology 2011; 114: 971-93.","journal-title":"Anesthesiology"},{"key":"480_CR20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mpaic.2014.07.011","volume":"15","author":"I Ahmed","year":"2014","unstructured":"Ahmed I, Jepegnanam C. Recognition and management of phaeochromocytoma. Anaesth Intensive Care 2014; 15: 465-9.","journal-title":"Anaesth Intensive Care"},{"key":"480_CR21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/bja\/83.2.302","volume":"83","author":"WJ Fawcett","year":"1999","unstructured":"Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth 1999; 83: 302-20.","journal-title":"Br J Anaesth"}],"container-title":["Canadian Journal of Anesthesia\/Journal canadien d'anesth\u00e9sie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12630-015-0480-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12630-015-0480-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12630-015-0480-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T18:07:26Z","timestamp":1653156446000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12630-015-0480-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,11]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["480"],"URL":"https:\/\/doi.org\/10.1007\/s12630-015-0480-2","relation":{},"ISSN":["0832-610X","1496-8975"],"issn-type":[{"value":"0832-610X","type":"print"},{"value":"1496-8975","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,11]]}}}